汇宇制药：依托泊苷注射液获得药品注册证书

Core Viewpoint - The company Huayu Pharmaceutical (688553.SH) has received approval from the National Medical Products Administration for its product, Etoposide Injection, which is indicated for various cancers, enhancing its competitive position in the market [1] Group 1: Product Approval - The Etoposide Injection is approved for treating small cell lung cancer, malignant lymphoma, malignant germ cell tumors, leukemia, neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, gastric cancer, and esophageal cancer [1] - The registration classification of Etoposide Injection is categorized as a Class 3 chemical drug, which has passed the consistency evaluation of quality and efficacy compared to reference preparations [1] Group 2: Market Impact - The approval of Etoposide Injection is expected to provide greater support in areas such as medical insurance payment and procurement by medical institutions due to national policies favoring drugs that pass consistency evaluations [1] - The successful consistency evaluation enhances the company's competitive capabilities and positively impacts its development [1]